The perspective comments on real world data published in Blood Cancer Journal by Aimaz Afrough Yi Lin Surbhi Sidana, MD Gurbakhash Kaur Larry Anderson,MD,PhD,FACP Shonali Midha, M.D. Hamza Hashmi Krina Patel Douglas W. Sborov MD MS Omar Nadeem et al.

nature.com/articles/s4140…

Want to learn more about novel therapies in SMM, non-drug interventions, ongoing trials in the field, and more?

Explore our roundtables from #IBC2024 below:

👉ow.ly/TLWj50R36gC

ft. Omar Nadeem, Urvi Shah, Bruno Paiva, Kwee Yong, Irene Ghobrial & more!

#MMsm

‼️ BREAKING NEWS ‼️
The 5th How to Diagnose & Treat MULTIPLE #MYELOMA will take place in Vienna 🇦🇹 on April 3-5, 2025!
SAVE THE DATE FOR #ESHMM2025 !
Chairs: Prof. Dr. Hermann Einsele, marivi mateos, Omar Nadeem
Learn more ➡ bit.ly/3THZibM
#ESHCONFERENCES #HAEMATOLOGY #HEMATOLOGY #MMsm

BREAKING: The FDA’s ODAC determined the risk/benefit assessment for cilta-cel for adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy and are refractory to lenalidomide to be favorable.

targetedonc.com/view/fda-s-oda…

IBC2024 kicking off in Lisbon, Portugal. Great to have a dedicated workshop focused on prevention of blood cancers VJHemOnc #mmsm

IBC2024 organized by Irene Ghobrial & Jesus San-Miguel begins today VJHemOnc #mmsm #leusm #lymsm
ibcworkshop.org
Nikhil C. Munshi, MD Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Shaji Kumar Lachelle Dawn Matthew Davids, MD, MMSc Sanam Loghavi, MD صنم لغوی 🔬🧬 Omar Nadeem marivi mateos Bruno Paiva Dr. Uma Borate: Associate Professor

Register for our March 27thth webinar “Evolving Myeloma Treatment Options: How You Can Access Cutting-Edge Care” with Omar Nadeem of @danafarber ow.ly/YmlZ50QIn5Q #bloodcancer #MMsm #CART #Bispecific

Fantastic time as always connecting with friends, mentors sharing and learning amazing science ASH nizar jacques bahlis Neha Korde Omar Nadeem Dr. Zelenetz

DFCI MM team celebrating a successful #ASH2023 meeting #mmsm #ASH23

Fantastic talk on #Duffynull by Lauren Merz Do yourself a favor and watch the educational spotlight if you didn’t make it in-person. #ASH23

#ASH23 #mmsm oral myeloma
Work on high risk SMM

This is important to understand genomics of smoldering myeloma

Clinical criteria does not really accurately identify patients with high accuracy

Still more to learn

Nice work by Ben Diamond, MD

#ASH23 Dont forget to checkout the younger, American sister to the #Plenary Iskia study! The SkyLark study, Isa-KRD in TE NDMM presented by Betsy O'Donnell Dana-Farber Mass General Cancer Center #mmsm
🔑ORR 100%!!
🔑91.3% PFS at 24 mos

Paul Richardson presenting results of MEZI + MoAB combinations in RRMM Dana-Farber #ASH2023 #ASH23 #mmsm

Immuno-PRISM study of 12 high risk SMM patients treated with BCMA-bispecific Tecvayli. Good activity, high rate of MRD negativity, improved safety profile compared to relapsed/refractory patients. #ASH23

Our Center for Early Detection and Interception of blood cancers (CEDI-BC) team Dana-Farber . Sharing data of Dara-RVD in HR-SMM with MRD response adaptive design Irene Ghobrial #mmsm #ASH2023

@lizlightbody presented our proteomics data demonstrating new biomarkers of disease progression #ash23 #mmsm

Very high activity with little disgeusia and skin toxicity. CAR-T may be the best way to hit GPRC5D. Terrific presentation by ⁦Susan Bal⁩ #ASH23 ⁦Jesus Berdeja, MD⁩ ⁦Larry Anderson,MD,PhD,FACP⁩ ⁦Omar Nadeem⁩